TuHURA Biosciences (NASDAQ:HURA) Stock Price Up 1.7% – Still a Buy?

TuHURA Biosciences (NASDAQ:HURA)’s share price shot up 1.7% on Thursday . The company traded as high as $3.72 and last traded at $3.62. 114,112 shares traded hands during mid-day trading, a decline of 59% from the average session volume of 276,926 shares. The stock had previously closed at $3.56.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on HURA. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target for the company. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Finally, HC Wainwright began coverage on TuHURA Biosciences in a report on Monday, March 3rd. They set a “buy” rating and a $13.00 price target on the stock.

TuHURA Biosciences Price Performance

The stock has a 50-day simple moving average of $3.58.

Hedge Funds Weigh In On TuHURA Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC bought a new position in TuHURA Biosciences during the 4th quarter worth approximately $1,084,000. Suncoast Equity Management bought a new position in TuHURA Biosciences during the fourth quarter worth $421,000. Apollon Wealth Management LLC acquired a new position in TuHURA Biosciences in the fourth quarter valued at $253,000. Northern Trust Corp bought a new stake in TuHURA Biosciences during the fourth quarter valued at $234,000. Finally, Squarepoint Ops LLC acquired a new stake in TuHURA Biosciences during the 4th quarter worth about $223,000. 0.62% of the stock is owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.